Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30923337 | 0.92 | DUT (0.35) | DUTHTR2A | |
| SCHEMBL30271106 | 0.83 | TAAR1 (0.43) | DUTIDO1 | |
| SCHEMBL6347925 | 0.83 | TAAR1 (0.43) | DUTIDO1 | |
| SCHEMBL1246807 | 0.82 | DUT (0.33) | DUTIDO1 | |
| SCHEMBL29876706 | 0.78 | HTR2A (0.30) | HTR2A | |
| SCHEMBL27033281 | 0.78 | HTR2A (0.30) | HTR2A | |
| SCHEMBL25824421 | 0.77 | HTR2A (0.37) | HTR2AIDO1 | |
| SCHEMBL30922793 | 0.76 | LPL (0.31) | — | |
| SCHEMBL6114675 | 0.75 | DUT (0.34) | DUT | |
| SCHEMBL9566221 | 0.75 | TAAR1 (0.41) | DUTHTR2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | DUT 4108/4885HTR2A 4429/4885IDO1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.